Goal of this study

To treat amyotrophic lateral sclerosis also known as Lou Gehrig’s disease, Charcot’s disease or motor neuron disease.


Amyotrophic Lateral Sclerosis (ALS) is a brain and spinal cord disease that causes muscle weakness and wasting and is due to deterioration of motor neurons which are the neurons that are important for body movement. This study will investigate the efficacy of a drug named Arimoclomol in patients with ALS. Arimoclomol will be given to the patient through the mouth for a period of 76 weeks.

Who can participate in this study?

Patients who have been diagnosed with amyotrophic lateral sclerosis and who are 18 years and older may be eligible to participate in this study. This study accepts both men and women and does not accept healthy volunteers.

Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.

Clinicaltrials.gov identifier: NCT03491462

Contact Information

To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.